Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rocgel
- Development stage
- Unknown
- Lead developer
- SERB Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rocgel is an antacid medication containing hydrated aluminum oxide (boehmite) as its active ingredient. It is formulated as an oral suspension, typically packaged in sachets, and is primarily used for the symptomatic relief of gastric pain, heartburn, and gastroesophageal reflux disease (GERD). Manufactured by SERB, Rocgel works locally within the gastrointestinal tract by neutralizing excess stomach acid and providing a protective layer to the esophageal and gastric mucosa. Clinical evidence indicates that its efficacy in relieving symptoms of reflux esophagitis is comparable to that of H2-receptor antagonists such as ranitidine.
- Brand names
- Rocgel
- Other names
- hydrated aluminum oxideboehmite
Beyond the preview
Go deeper on Rocgel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rocgel.